Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma
Condition: B-cell Adult Acute Lymphoblastic Leukemia; B-cell Childhood Acute Lymphoblastic Leukemia; B-cell Chronic Lymphocytic Leukemia; Childhood Burkitt Lymphoma; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Post-transplant Lymphoproliferative Disorder; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Testicular Lymphoma; Waldenström Macroglobulinemia
MeSH terms: Burkitt Lymphoma; Lymphoma; Leukemia; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphoid; Lymphoma, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Hodgkin Disease; Lymphoma, Mantle-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Immunoblastic; Plasmablastic Lymphoma; Waldenstrom Macroglobulinemia; Leukemia, Hairy Cell; Lymphomatoid Granulomatosis; Lymphoma, Extranodal NK-T-Cell; Intraocular Lymphoma; Lymphoproliferative Disorders; Recurrence
Intervention: rituximab; peripheral blood stem cell transplantation; nonmyeloablative allogeneic hematopoietic stem cell transplantation; pharmacological study; laboratory biomarker analysis
Intervention description: Given IV; Undergo nonmyeloablative allogeneic peripheral blood/hematopoietic stem cell transplantation; Undergo nonmyeloablative allogeneic peripheral blood/hematopoietic stem cell transplantation; Correlative studies; Correlative studies
Intervention MeSH terms: Rituximab
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 63.0
Sex: All
Healthy volunteers: No

Summary:

      This phase II trial studies giving rituximab before and after a donor peripheral blood stem
      cell transplant in patients with B-cell lymphoma that does not respond to treatment
      (refractory) or has come back after a period of improvement (relapsed). Monoclonal
      antibodies, such as rituximab, can interfere with the ability of cancer cells to grow and
      spread. Giving rituximab before and after a donor peripheral blood stem cell transplant may
      help stop cancer from coming back and may help keep the patient's immune system from
      rejecting the donor's stem cells.
    

Eligibility criteria:

        Inclusion Criteria:

          -  With a diagnosis of CD20-expressing B-cell malignancy of any histologic type or grade
             for whom non-myeloablative allogeneic transplant is considered an appropriate
             treatment option

          -  Who are enrolled on a non-myeloablative allogeneic HCT protocol employing total-body
             irradiation (TBI)-based conditioning of =< 4.5 Gy, with or without fludarabine; this
             protocol may be used as an adjunct to the allogeneic arm of a tandem
             autologous/allogeneic transplant protocol, provided the allogeneic conditioning meets
             the above criteria

          -  Receiving unmodified peripheral blood mononuclear cell graft products

          -  With an appropriate related or unrelated donor; human leukocyte antigen
             (HLA)-haploidentical donors are excluded

          -  Able to give informed consent (if >= 18 years of age), or with a legal guardian
             capable of giving consent (if < 18 years of age)

        Exclusion Criteria:

          -  Ineligible for non-myeloablative allogeneic HCT

          -  Receiving an HLA-haploidentical allograft

          -  Who are fertile but unwilling to use contraception during and for at least 12 months
             after HCT

          -  Females who are pregnant or breast-feeding